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Abstract Immunohistochemical studies showed that
O6-methylguanine-DNA methyltransferase (MGMT) pro-
tein expression is negatively associated with survival in glio-
blastomas treated with alkylating agents in accordance with
previous results of methylation-speciWc PCR. Implementa-
tion of this data in routine clinical diagnostics is limited due
to often inappropriate study designs, e.g. pooling of tumor
entities, WHO grades or primary and secondary glioblasto-
mas, disregard concerning the inWltration zone or various epi-
demiological factors. The aim of our study was to evaluate
MGMT expression and its prognostic value taking into con-
sideration the aforementioned deWciencies. For this, 162
astrocytic tumors WHO II–IV (36 diVuse astrocytomas
WHO II, 51 anaplastic astrocytomas, 75 primary glioblasto-
mas) as well as 25 glioblastoma inWltration zones and 19
glioblastoma relapses were analyzed for immunohistochemi-
cal MGMT protein expression using tissue microarray tech-
nique. Expression of MGMT signiWcantly decreased from
WHO grade II (25.6%) to glioblastoma (16.8%, p = 0.01)
with lowest levels in grade III tumors (10.2%, II/III
p < 0.0001). SigniWcant negative associations of MGMT and
survival were detected for WHO grade II and IV (p = 0.003
and 0.013). The optimal cut-oV value of MGMT positive
nuclei in primary glioblastomas discriminating patients with
signiWcantly diVerent survival rates was at 15% (Log–Rank
p = 0.0002). Individual relapse tumors showed changes of
MGMT expression to a varying degree. The inWltration zone
demonstrated a signiWcant increase of MGMT (p < 0.0001).
We conclude that immunohistochemical MGMT assessment
has potential as a powerful diagnostic tool but analysis
should only be performed in a grade dependent manner,
before radio-/chemotherapy and with special attention to the
inWltration zone of diVuse astrocytomas.
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Introduction
Recently, the EORTC (European organisation for research
and treatment of cancer) study with temozolomide in con-
junction with radiotherapy after surgical resection demon-
strated a signiWcantly prolonged median patient survival,
albeit only for single months [40]. Further analysis of
the DNA-repair gene MGMT (O6-methylguanine-DNA
methyltransferase also known as AGT, NC-IUBMB:
E.C.2.1.1.63) methylation status demonstrated a signiWcant
survival beneWt solely for patients with a silenced MGMT
gene as detected by methylation-speciWc polymerase-chain-
reaction analysis (MSP) in the group treated with radio-/
chemotherapy [16]. This conWrmed previous results of a
correlation of MGMT inactivation and clinical response to
alkylating agents (e.g. temozolomide, nitrosourea) [11, 12, 18].
Besides MSP [11, 15, 34, 46] and RNA detecting meth-
ods [33, 42], the measurement of MGMT enzyme activity
and the immunohistochemical (IHC) detection of MGMT
protein have been employed repeatedly to assess the in vivo
MGMT status [1, 8, 25, 39, 48]. In a recent comparison a
signiWcant correlation of IHC MGMT evaluation with MSP
as well as MGMT enzyme activity was demonstrated, while
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discordance concerning the prognostic properties of MSP
and IHC MGMT detection was assumed [23]. The explana-
tory power of this analysis remains limited though, as only
a small number of pooled tumor samples were investigated
and the prognostic groups were not conWrmed with an
actual survival beneWt. If MGMT status is intended to guide
future therapeutic practice the need for further standardiza-
tion of MGMT testing is urgent.
Immunohistochemistry (IHC) presents several advanta-
ges for the detection of MGMT status, predominantly techni-
cal aspects (fast and easy to do, little material required,
endothelia as internal positive control, material can be
archived in paraYn, antibodies commercially available with
mostly used clone mT3.1, see [5]) but also oVers additional
diagnostic information such as the visual discrimination of
tumor cells from non-neoplastic cells. There is strong evi-
dence for clonal heterogeneity of gliomas for MGMT methyl-
ation [2] and that modiWcations besides promoter methylation
such as MGMT mutations or p53 derangement may aVect the
functional in vivo protein levels [3, 9]. By measuring the
endpoint of these regulations, IHC MGMT detection avoids
several of these pitfalls. Nevertheless, IHC has several short-
comings, in particular tumor inWltration by MGMT positive
inXammatory cells [29], as well as the possible induction of
MGMT by radio-/chemotherapy [13, 47]. The main problem
with the interpretation of IHC MGMT status though, is an
often insuYcient study design. Glial tumors of various
WHO grades with known prognostic diVerences or primary
and secondary glioblastomas are pooled in a single group and
analyzed for prognosis, the total sample size is often low,
and cut-oV values have been selected arbitrarily.
In the current study we have addressed several of the
above shortcomings of IHC MGMT detection and
attempted to establish non-arbitrary cut-oV values for future
prospective studies as well as routine clinical evaluation.
For this purpose, the IHC expression of MGMT is ana-
lyzed in a large array of diVuse astrocytomas of WHO
grades II, III and IV, and associations with survival are
evaluated independently for each grade. For grade IV, only
primary glioblastomas at Wrst occurrence are taken into
analysis. To evaluate if radio-/chemotherapy has an impact
on in vivo MGMT expression of glioblastomas, primary
glioblastomas are investigated before and after therapy.
Finally, special attention is given to inWltration versus cen-
tral areas of glioblastomas.
Materials and methods 
Human tissue specimens 
A total of 162 brain tumor samples from the tumor bank of
the Institute of Brain Research (Neuropathology), University
of Tübingen were investigated. The patients underwent
surgical treatment from 1993 to 2003. The specimens
consisted of 36 WHO grade II astrocytomas (29 Wbrillary,
5 gemistocytic, 2 protoplasmic; 19 M, 17 F, median age
38 years), 51 grade III anaplastic astrocytomas (32 M, 19 F,
median age 44 years) and 75 WHO grade IV glioblastomas
(44 M, 31 F, median age 59 years), and they were diag-
nosed according to the WHO criteria for tumors of the ner-
vous system by two senior neuropathologists (RM, MM)
[20]. For grade IV, only primary glioblastomas were ana-
lyzed. Resection data as determined postoperatively by the
neurosurgeon was available for 147 cases with 50 cases of
complete macroscopic resection and 97 cases with incom-
plete resection. No tumor biopsies were integrated into this
study. Additionally, 25 inWltration zones and 19 relapses of
glioblastomas were included. All patients with relapse
received Weld radiotherapy of up to 60 Gray and chemo-
therapy to a varying degree. Of six tumor specimens nor-
mal appearing white matter distant from the tumor was
analyzed as a reference of MGMT expression in uninWl-
trated brain. Usage of the tissue was approved by the local
ethics committee.
Follow up for glioma patients was up to 12.6 years.
Within this time frame a total of 99 patients died after a
median survival of 13.9 months (range 1–151) whereas 54
were still alive with a median follow-up of 27.6 months
(range 1–136). Nine patients were lost the trace immedi-
ately after operation. These patients were not included in
survival analysis.
All specimens were Wxed in 4% formalin (pH 7.4),
embedded in paraYn and representative tissue samples
were prepared as a tissue microarray (TMA) (punch diame-
ter, 0.6 mm) as previously described [27]. The TMA blocks
were cut with a microtome (3 m thickness) and placed on
SuperFrost Plus slides (Microm International, Walldorf,
Germany).
Immunohistochemistry
The slides were deparaVinized in chloroform for 20 min
then rehydrated in descending series of ethanol and washed
in Tris-buVered saline (TBS). For antigen retrieval we used
a simpliWed adaptation of the method introduced by
Namimatsu and colleagues [30], boiling the slides in 0.05%
citraconic anhydride (pH 7.4) in a microwave oven at max-
imum power (800 W) for 20 min, and then let the slides
cool down to room temperature. Endogenous peroxidase
was blocked with 3% H2O2 in methanol for 15 min, and
standard swine serum was applied for 15 min to prevent
nonspeciWc binding. As primary antibody we used
monoclonal mouse anti-MGMT antibody clone MT3.1
(Chemicon, Temecula, USA) in a dilution of 1:75 and sec-
tions were incubated overnight at 4°C. Subsequent to
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washes in TBS for 10 min, sections were incubated for
30 min with the secondary antibody at room temperature.
The peroxidase-conjugated avidin–biotin complex (ABC)
technique (Dako, Hamburg, Germany) with diaminobenzi-
dine (DAB; Sigma, Deisenhofen, Germany) as chromogen
was used to visualize the antigen binding. All sections were
counterstained with hemalaun.
As negative controls (isotype control), every slide was
also treated with replacement of primary antibody with a
monoclonal IgG1 antibody for an Aspergillus niger surface
protein (Dako Cytomation), a protein structure not
expressed in mammalian tissue. None of the tumors
showed an unspeciWc nuclear stain.
Evaluation
Evaluation of the immunohistochemical staining and
photographic documentation was performed using an
Olympus Vanox AHBT3 microscope. All slides were
investigated individually by two experienced investiga-
tors and a mean score of both observations was used for
statistics. Four cases were not possible to evaluate and
were omitted from further analysis (see “Results”). At
least 100 cells were evaluated for nuclear MGMT stain-
ing. Endothelial cells and perivascular lymphocytes were
omitted from analysis. A weak staining of the nucleus was
counted as positive. Granular staining of the nucleus was
not observed. Cytoplasmic staining was not counted as
positive.
Statistical analysis
The means were compared by a one-way analysis of vari-
ance (ANOVA) with subsequent Tukey–Kramer’s HSD
test with a global signiWcance level of 5%. For signiWcant
diVerences individual p values were calculated. For individ-
ual pairwise comparisons we used a one sample t test. For
assessing correlations between age and MGMT expression
an analysis of linear regression was used. The means
are given together with their 95% conWdence intervals
(CI), signiWcant diVerences are illustrated (*p · 0.05,
**p · 0.01, ***p · 0.0001). We chose a two-step survival
analysis with the validation of a global association in an
exponential parametric survival Wt for each grade and a
subsequent Kaplan Meier analysis. A signiWcant global
association with survival was set as a requirement to per-
form the dichotomy of the percental values for Kaplan
Meier analysis. Grades II and IV met the above require-
ments and were repeatedly divided into two groups at 5%
intervals for optimal cut-oV values. A designated group was
never allowed to be less than Wve patients. For adjustment
of the p values due to multiple testing we used the method
of Bonferroni. JMP IN (http://www.JMP.com) was used for
statistical analysis.
Results
MGMT expression decreases signiWcantly from low 
to high-grade gliomas
The vast majority of cases investigated demonstrated a
moderate to strong nuclear stain for MGMT in at least some
tumor cells (Fig. 1a–c). Generally, most endothelial nuclei
as well as inWltrating inXammatory cells were strongly
MGMT positive and endothelial nuclei served as an
internal positive control. In endothelia, an additional weak
cytoplasmic stain was regularly observed (Fig. 1a). As
previously noted, we observed a droplet like cytoplasmic
stain in few cases (one case of grade II, 11 cases of grade
III) [24]. Matching these cases with the isotype control
revealed that the staining does not represent cytoplasmic
MGMT, but is nonspeciWc (Fig. 1d, e). Importantly, no
cases with an unspeciWc nuclear reaction were observed in
the isotype control. Four cases (one grade II, one grade III,
two grade IV) could not be evaluated for MGMT expres-
sion by IHC, as the nuclear reaction was too weak to clearly
diVerentiate positive and negative cells (Fig. 1f). The aver-
age levels of stained tumor cells were higher in low grade
compared to high grade tumors with a mean expression of
25.6% (CI 20.1–31.1%) in diVuse astrocytoma WHO grade
II, decreasing to 10.2% (CI 5.6–14.8%) in anaplastic astro-
cytoma grade III and 16.8% (CI 13.0–20.6%) in glioblas-
toma WHO grade IV (Fig. 2). The decrease was signiWcant
(II/III p < 0.0001; II/IV p = 0.01) while the signiWcance
between grade III and IV was lost after correction for multi-
ple testing (III/IV p = 0.031). Six tumor cases with uninWl-
trated white matter showed high levels of positive glial
cells [mean 77.2% (CI 60.7–93.6%)] and all demonstrated a
clear reduction of MGMT-positive nuclei in the tumor tis-
sue (data not shown). Expression in uninWltrated grey mat-
ter was lower than in white matter with neurons generally
negative for MGMT (data not shown).
MGMT expression is signiWcantly higher in glioblastoma 
inWltration zone compared to tumor center 
A highly signiWcant increase of nuclear MGMT expression
was observed in the inWltration zone of the investigated
glioblastomas compared to the corresponding tumor center
(p < 0.0001). The mean expression was 43.9% (CI 35.3–
52.5%) in the inWltration zone compared to 16.1% (CI 7.7–
24.5%) in the subset of glioblastomas (Fig. 3). The mean
expression of the inWltration zone was clearly lower than
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the mean expression of uninWltrated white matter (see
above).
In vivo MGMT expression does not shift unidirectionally 
after radio-/chemotherapy
While the mean expression of MGMT in the group of
relapse glioblastomas demonstrated an increase from
14.3% (CI 6.9–21.6%) in the primary tumors to 20.4% (CI
13.1–27.7%) in the relapses, a matched pairs analysis could
not show signiWcant diVerences (p = 0.20; Fig. 4). Several
tumors demonstrated a considerable change of individual
MGMT expression, but both, a clear increase as well as a
Fig. 1 Patterns of MGMT expression in diVuse astrocytomas.
a Glioblastoma with disseminated MGMT positive cells while the
majority of tumor cells are negative. Intermingled strongly positive
endothelia with additional weaker cytoplasmic stain are also visible
(arrow). b DiVerent glioblastoma showing strong MGMT expression
in majority of tumor cells. c DiVuse astrocytoma WHO II with strong
MGMT expression in most cells. d Anaplastic astrocytoma with strong
droplet like cytoplasmic stain and single positive nuclei, most likely
lymphocytes (arrows). e Although weaker, the cytoplasmic reaction is
also visible in the isotype control of same tumor, delineating it as
unspeciWc (arrows). f DiVuse astrocytoma WHO II with too weak
MGMT expression to discriminate positive and negative cells. The tu-
mor was omitted from further statistical analysis [magniWcation £200
(a–c and f); £400 (d and e); scale bar 100 m]
Fig. 2 Percental MGMT expression in astrocytoma WHO grade
II–IV. Depiction of means and 95% CI. A signiWcant decrease was
observed from WHO grade II to grade III and IV
Fig. 3 Depiction of a matched pairs analysis of MGMT expression in
tumor center and inWltration zone of glioblastoma. Corresponding
pairs are connected by a line. All cases showed an increase in expres-
sion in the inWltration zone (p < 0.0001)
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clear decrease was observed. Three change of expression
groups were distinguished in relation to the mean diVerence
of all cases, one group with a clear decrease of MGMT
(red, n = 5 of 19) with a reduction beyond the CI of the
mean diVerence, the second with no individual changes
(black, n = 7 of 19) (diVerence within 95% CI) and the third
with a clear increase of MGMT out of the range of the 95%
CI (yellow, n = 7 of 19). No further association of the
groups with individual chemotherapy was seen (data not
shown).
MGMT is negatively associated with survival in WHO 
grade II and IV 
The survival analysis for WHO grade II, III and IV tumors
showed a signiWcant association in the parametric expo-
nential survival Wt of grades II and IV (p = 0.003 and
0.013, respectively; Figs. 5, 6) while grade III tumors
demonstrated no such association (p = 0.18, data not
shown). Even for the subgroup of WHO grade III tumors
that received an alkylating therapy (n = 19) no signiWcant
results were obtained (p = 0.88, data not shown). For both
grades II and IV, low levels of MGMT were associated
with a better patient survival. Further analysis for an opti-
mal cut-oV value for prognostic evaluation demonstrated
that for grade II, MGMT expression in 35% of the tumor
cells was the delimiter with the best p value (Table 1).
The median survival was 44.4 months (mean 63.8, range
1–151) for low MGMT expression in contrast to
10.4 months (mean 31.6, range 3–89) in the high MGMT
group. The division of WHO grade II cases at 35% led to
two groups of clearly diVerent size, indicating that a small
group of patients with high MGMT expression (n = 6)
were predominantly responsible for the association with
survival.
In grade IV the optimal value for a dichotomy was found
at 15% MGMT positive cells (Table 1). This value highly
discriminated between patients with a good prognosis and
patients with a poor prognosis (Log–Rank p = 0.0002;
Fig. 6). Median survival for the group with low expression
Fig. 4 Glioblastoma MGMT expression before and after therapy.
Depiction of a matched pairs analysis of primary tumor and corre-
sponding relapse (connected by line). Although the analysis did not
indicate a signiWcant unidirectional change of expression (p = 0.20),
several individual tumors showed a marked alteration of nuclear MG-
MT. Red lines connect cases with a decrease beyond 95% CI of mean
diVerence, yellow lines an increase beyond 95% CI of mean diVerence,
black lines are within 95% CI
Fig. 5 MGMT expression is associated with survival in grade II astro-
cytoma with high levels correlating with a worse survival. a Depiction
of exponential parametric survival Wt (note the log scale) with survival
time in relation to MGMT expression (%). Squares reached Wnal end
point, small dots represent censored data. The analysis demonstrates a
highly signiWcant association of worse survival with high expression
(p = 0.003). For illustration, the groups for Kaplan Meier analysis are
surrounded by a green and a red box, splitting the cases at 35% MGMT
expression. b Kaplan Meier analysis of same data demonstration a
highly signiWcant discrimination of the two prognostic groups (Log–
Rank p = 0.005) 
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was 15.4 months (mean 17.9, range 1–75) compared to
8.0 months (mean 10.2, range 1–34) for the group of high
MGMT expression. The diVerences in group-size at this
cut-oV value were within reasonable limits.
Correlation of MGMT expression and patient age 
In the analysis of associations between MGMT expression
and patient age a marginally signiWcant positive correlation
was detected for grade II and a strong trend for grade IV
(p = 0.046 and 0.052; Fig. 7), whereas WHO grade III dis-
played no association (p = 0.27; data not shown).
As for grade II all patients with a worse prognosis were
old (Fig. 7a), it seems evident that for grade II the associa-
tion of MGMT expression and survival was predominantly
by the diVerence of age, which is a well-known predictive
factor of survival.
MGMT retains its association with survival in peak age 
group of glioblastoma
To verify that the association of MGMT with survival in
glioblastoma is not an eVect of its near correlation with age
(Fig. 7b), glioblastoma cases were reduced to the peak age
group of patients from 45 to 70 years [20], thus omitting
patients with extreme age deviations from the analysis.
Even for the smaller sample group the signiWcance for the
association with survival remained in the exponential para-
metric survival Wt (p = 0.035; Fig. 8a) as well as in the
Kaplan Meier analysis with a signiWcant discrimination of
patients with good and bad prognosis at the previously
established cut-oV value of 15% (p = 0.011; Fig. 8b). For
the reduced group, no association of patient age and
MGMT expression was detectable (p = 0.147, data not
shown).
Discussion 
Future glioma therapy will consider tumor MGMT status
and possibly stratify patients by their MGMT expression
[14]. Several studies using methods such as MSP and IHC
have demonstrated an association of MGMT status and sur-
vival (IHC [1, 7, 12, 29, 35]; MSP [10, 11, 15, 16, 34, 45])
while other groups could not or only partially detect associ-
ations with survival [2, 4, 19]. Recently in reaction to an
IHC study of MGMT in inoperable newly diagnosed glio-
blastoma patients [7], MSP was clearly advocated for the
detection of MGMT status [41].
It is worth mentioning that MSP also has distinct short-
comings. Astrocytomas are very heterogeneous tumors,
both in histology and (epi)-genetics, and this is also true for
the methylation of the MGMT promoter as demonstrated by
Blanc et al. [2]. In a recent comparison of IHC and MSP,
Maxwell noted that even in MSP negative tumors (where
MGMT is not silenced) a large fraction of potentially tem-
ozolomide sensitive MGMT negative cells is present and in
MSP positive tumors (where MGMT is silenced) large frac-
tions of MGMT positive cells can be found. MSP has the
great advantage of oVering an explicit MGMT status,
though it seems as if the method artiWcially divides gliomas
into black and white, and does not take into account the het-
erogeneous nature of these tumors. This makes therapeutic
decisions on the basis of MSP status alone somewhat unsat-
isfactory. It is possible, that MGMT methylation status
Fig. 6 MGMT expression 
is associated with survival in 
glioblastoma with high levels 
correlating with a worse survival 
(as in Fig. 5, except for splitting 
the boxes at a cut-oV value 
of 15%)
Table 1 Log–Rank p-values of Kaplan Meier analysis for the cut-oV
at diVerent percental MGMT expression for WHO grade II and IV 
The p value for a signiWcant result after Bonferroni correction
was p < 0.007 for grade II and p < 0.006 for grade IV
n.a. Not applicable
Cut-oV level (%) WHO II WHO IV
5 n.a. p = 0.42
10 p = 0.68 p = 0.13
15 p = 0.12 p = 0.0002
20 p = 0.3 p = 0.001
25 p = 0.29 p = 0.004
30 p = 0.08 p = 0.02
35 p = 0.005 p = 0.02
40 n.a. p = 0.04
50 p = 0.03 p = 0.03
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functions as a surrogate for multiple gene silencing activi-
ties throughout the tumor with the inactivation of further
prognostically relevant genes. This theory may also explain
why several investigators have observed an MGMT sur-
vival beneWt irrespective of actual treatment with an alkyl-
ating agent [10, 16]. Other results are further detaching
MGMT methylation status from actual cellular MGMT lev-
els, as recently p53 has been shown to regulate cellular
MGMT independently of methylation status [3].
A possible reason why IHC has not (yet) found its way
into clinical routine may be the lack of consistently deW-
ned cut-oV values for prognostic groups. Some of the dis-
crepancies could be explained by the investigation of
diVerent patient collectives. Indeed, as our results indicate
a trend of increased MGMT expression in old age, varia-
tions in the mean age of investigated patients may well
change the optimal cut-oV value. We therefore established
the cut-oV for the peak age group of glioblastoma as deW-
ned in the WHO ClassiWcation [20]. Further, our results
were able to demonstrate a signiWcant decrease from low
to high-grade diVuse astrocytoma, an observation that is
supported by other studies [26, 36, 48] and clear diVer-
ences between grade III and IV tumors. This clearly dis-
qualiWes the pooling of astrocytoma grades for survival
analysis. Our study did not integrate secondary glioblasto-
mas for the reasons that (1) the genetic pathways leading
to primary or secondary glioblastoma diVer at several lev-
els [32], (2) secondary glioblastomas only constitute a
small subgroup of glioblastomas [31], (3) p53 levels,
known to inXuence MGMT status, clearly diVer in pri-
mary and secondary glioblastoma [44], and (4) the meth-
ylation of MGMT promoter shows signiWcantly higher
levels in secondary glioblastomas [28].
All these factors may in part explain the wide range of
cut-oVs in use for “high-grade” glioma ranging from <5 to
35% [1, 4, 7, 12, 29, 35]. As Table 2 indicates, most IHC
studies conducted so far pooled several WHO grades, some
even oligodendroglial and astrocytic tumors. Of the two
studies with values exclusive for grade IV, Chinot et al. [7]
investigated the subgroup of inoperable tumors, a group
Fig. 7 Correlation of age and MGMT in grade II and IV. Green
squares correspond to good prognosis group, red to bad prognosis (see
Figs. 5 and 6). a The depiction of grade II MGMT expression in rela-
tion to age shows that all patients with a high expression were older
than 50 years. No patients under 50 years were in the group of bad
prognosis. The linear regression reached marginal signiWcance
(p = 0.046). b For grade IV the association showed a strong trend
(p = 0.052) but did not reach signiWcance. Likewise, the illustration
shows that higher expression (above 25%) is exclusively found in older
patients
Fig. 8 Even in the reduced peak age group of glioblastoma MGMT re-
tains its association with survival. a Illustration of exponential para-
metric survival Wt demonstrating a signiWcant association of survival
and MGMT even in the peak age group of glioblastoma (45–70 years).
b Kaplan Meier analysis at the previously established cut-oV value of
15% also remains signiWcant for the peak age group
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with a survival not comparable to the general patient collec-
tive and in the study of Anda et al. [1] analysis was limited
to 18 primary glioblastomas. Further factors that are likely
to inXuence the results are technical factors of the IHC pro-
cedure and interobserver variability. For a standardized
IHC procedure we performed an adoption of the antigen
retrieval method of Namimatsu et al. [30]. Interobserver
variability should be evaluated in a larger multi-institu-
tional study to determine the number of patients ending up
in divergent prognostic groups, thereby further elucidating
the feasibility of IHC MGMT status detection with our pro-
posed cut-oV.
In this study on astrocytic tumors, only grade II and IV
tumors demonstrated an association with survival, whereas
grade III tumors did not. Likewise, Brell demonstrated a
lack of association of MGMT methylation with survival as
well as MGMT IHC for a pooled group of grade III gliomas
(anaplastic astrocytoma, anaplastic oligodendroglioma, and
anaplastic oligoastrocytoma) [4]. It is noteworthy that Brell
and colleagues demonstrated an association of IHC and sur-
vival in a secondary analysis of a subgroup of patients
treated with an alkylating agent, whereas the same analysis
remained insigniWcant in our cohort. Thus, it is possible
that the results of Brell were strongly inXuenced by the
inclusion of tumors with an oligodendroglial diVerentiation
which are potentially more susceptible to chemotherapy
[6], whereas for anaplastic astrocytomas even post-alkylating
therapy survival seems to be independent of MGMT status.
Our results give new input to the current discussion on the
lack of justiWcation for temozolomide as the Wrst line treat-
ment for anaplastic astrocytoma (reviewed in [38]). In con-
trast, MGMT expression was elevated in WHO grade II
tumors and uninWltrated white matter, indicating that their
DNA repair mechanisms function on a higher level. In gen-
eral, this seems desirable, as high MGMT levels are likely
to counteract genetic alteration (e.g. spontaneous mutations
by endogenous DNA alkylation) that might lead to tumor
development and progression [22]. For the treatment of
low-grade astrocytomas this poses a problem though, as
several therapeutic substances depend on a reduced DNA
repair mechanism of tumor cells.
A recent MGMT methylation study of 27 Wbrillary astro-
cytomas grade II could not detect a signiWcant relationship
with overall survival [46] while a cohort of 49 grade II
astrocytomas identiWed MGMT methylation even as an
adverse indicator of recurrence free survival [21]. Data con-
cerning the time to relapse could not be integrated into this
study because of the small number of assessable cases. Two
explanations for the discrepancy to our results are conceiv-
able. (1) Our group of grade II tumors did not entirely con-
sist of Wbrillary astrocytomas given that Wve gemistocytic
and two protoplasmic tumors were also included. For
gemistocytic astrocytomas a more aggressive behavior has
been described [20]. In an analysis omitting these tumors,
the parametric survival Wt remained signiWcant (p = 0.016),
proving that these tumors are not causing the discrepancy.
(2) Our data for grade II demonstrated a signiWcant positive
correlation to patient age with expression above 35% exclu-
sively found in patients above 50 years. To our knowledge,
a signiWcant positive association of age and MGMT expres-
sion in WHO grade II tumors has not been described to
date. This association may partially contribute to the very
strong prognostic power of age in grade II tumors [31]; on
the other hand it complicates the interpretation of the pre-
sented data. Our cut-oV of 35% for grade II, forming one
small group of old patients with high expression and bad
prognosis does not suit the standards that we aimed to
establish by this study and therefore we suggest further
evaluation on the signiWcance of MGMT in diVuse astrocy-
toma WHO grade II.
Our study represents the largest observation of IHC
MGMT expression in primary glioblastoma before treat-
ment and oVers a highly signiWcant cut-oV value for the fur-
ther evaluation of prognostic groups. To our knowledge a
Table 2 IHC studies determining a cut-oV value for MGMT methylation status 
AA Anaplastic astrocytoma, AO anaplastic oligodendroglioma, AOA anaplastic oligoastrocytoma, n.a. not applicable
Study MGMT 
antibody 
clone
Cut-oV for 
prognostic 
groups (%)
Number of 
cases and WHO 
grade
Association 
with overall 
survival
Special Primary/secondary 
glioblastoma
Friedman et al. [12] MT3.1 20 38; 5 AA (III), 33 IV n.a. 37% Biopsy only Primary
Anda et al. [1] Mouse 
monoclonal
19 18; IV p = 0.01 Primary
Nakasu et al. [29] MT3.1 10 61; III and IV p = 0.009 Not declared
Brell et al. [4] MT3.1 <5 93; 75 AA (III), 
18 AO&AOA (III)
p = 0.066 33% Biopsy only Newly diagnosed 
WHO grade III
Pollack et al. [35] mT23.2 >25 109; III and IV p = 0.17 Childhood glioblastoma Primary
Chinot et al. [7] MT3.1 35 25; IV p = 0.004 Inoperable tumors only Primary
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trend of MGMT increase with age in glioblastoma has not
been described yet. In contrast, Silber et al. demonstrated
that MGMT enzyme activity is inversely correlated with
age in glioblastoma [39] and results of semi-quantitative
RT-PCR indicate an equivalent correlation on the gene
expression level in primary glioblastomas [37]. The dis-
crepancy of high protein levels and low enzyme activity
could possibly be explained by several loss of function
mutations in the MGMT gene that have been identiWed in
mutagenesis studies, although the in vivo prevalence of
these mutations has not been documented [9]. However, the
results of other studies could demonstrate a signiWcant cor-
relation of MGMT enzyme activity and immunohistochem-
ical labeling [23], casting the above explanations into doubt
and oVering a sampling eVect as a more likely reason for
the discrepancy.
A further aspect we tried to elucidate with this study was
the proposed induction of MGMT by radio-/chemotherapy
[13, 47]. For this, a cohort of primary glioblastomas was ana-
lyzed before and after radiotherapy and alkylating chemo-
therapy. No statistically signiWcant unidirectional change of
MGMT expression was detected although almost three-quar-
ter of the tumors showed marked changes out of the CI range
of their MGMT proWle. The cause of these changes remains
enigmatic. In contrast, Nakasu et al. [29] could not detect
changes of MGMT expression in recurrent gliomas in a
smaller cohort. Still, our results lead us to the conclusion that
considerable changes can be observed after therapy and our
proposed cut-oV value of 15% should only be applied before
application of radio-/chemotherapy. In case of a relapse the
reevaluation of MGMT tumor status seems necessary.
Besides chemotherapy other drugs have also been impli-
cated in interfering with MGMT expression with contrary
results found in literature, foremost glucocorticoids [17,
43]. Although many of our high-grade astrocytoma patients
received dexamethasone, the dosages and application inter-
vals before operation were not traceable and no statistical
analysis regarding this question could be performed.
In an analysis of further possible sources of error the
inWltration zone of diVuse astrocytoma demonstrated a con-
siderable increase of MGMT. It is important to note that a
clear histological discrimination of tumor cells and inWl-
trated normal brain cells was not possible. As we observed
high levels of MGMT in normal brain astrocytes and oligo-
dendrocytes, the high levels in the inWltration zone most
probably represents residual non-neoplastic cells [29]. This
Wnding is problematic for several methods of MGMT
detection. In IHC, small samples of tissue might only con-
tain inWltration zone and might therefore be perceived as
falsely high MGMT expressing tumors; MSP analysis
might reveal false negative results as the proportion of
tumor cells in the selected material might be too low. High-
grade gliomas are further known to be inWltrated by MGMT
positive non-neoplastic cells (mostly lymphocytes and
macrophages/microglia) constituting up to 7% of the total
tumor cells [29]. In IHC, it is often not possible to distin-
guish monocytes from neoplastic astrocytes in routine
staining and routine immunohistochemical double staining
is not practicable. As our proposed cut-oV of 15% lies well
beyond the observed maximum of 7% non-neoplastic cells,
we conclude that these cells are generally summed up in the
group of low expression and in general will not further
interfere with the evaluation.
As we aspire to propose a standardized procedure for
immunohistochemical evaluation several points for routine
diagnostics need to be addressed: What region of the tumor
should be evaluated? In this study we selected areas with
the most prominent signs of atypia/anaplasia, especially
cellular density and nuclear polymorphism. Still cases with
diverging MGMT expression in equally atypical regions
may be observed; in this case we propose evaluating the
area with the higher staining indices as these cells suppos-
edly determine survival. When is an MGMT stained cell
counted as positive? Equivalent to the staining of p53 and
other nuclear markers like progesterone receptor the
MGMT staining is not of an on/oV type, as every shade of
staining was detected. This is a risk for a signiWcant
observer bias. In our investigation we decided to even
count weak staining as positive, as results with the highly
sensitive nested in situ RT-PCR indicated that immunohis-
tochemical evaluation underrate the actual MGMT protein
expression [33]. What about the inWltration zone? We pro-
pose that immunohistochemical evaluation should only be
performed when the tumor can be unequivocally identi-
Wed. Especially in low-grade diVuse astrocytoma this can
cause serious problems. In cases of uncertainty we propose
not to evaluate MGMT by IHC alone. What cells should be
evaluated? We propose to count all cells except vascular
endothelia and perivascular lymphocytes as our cut-oV is
suYciently high to ensure that counted macrophages/
microglia will not alter prognostic status. A further dis-
crimination is simply not workable for fast routine diag-
nostics.
In conclusion, we were able to demonstrate that the
evaluation of MGMT status for glioma should be per-
formed strictly grade dependent. We propose further
investigations of the relation of survival and MGMT
expression in grade II and urge to analyze the eVect of age
adequately in further studies. The lack of association with
survival in grade III may be a representation of the diVer-
ent biological behavior and altered response to chemo-
therapy although further studies are needed to verify our
results. As even the patients receiving alkylating thera-
peutics showed no association of survival and MGMT,
possibly other Wrst-line therapeutic approaches should be
sought for WHO grade III astrocytomas.
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For de-novo grade IV glioblastomas we were able to
establish an optimal cut-oV value of 15% MGMT positive
nuclei for maximal discrimination of prognostic groups.
Finally, we conclude that the current methods of identi-
fying MGMT status should not lead to a status dependent
therapy with possibly not treating MGMT positive patients,
as the heterogeneous aspect of every investigated tumor
indicates a fraction of potentially chemotherapy sensitive
cells. If patient tailored therapy is sought, further under-
standing of MGMT regulation and further molecular deter-
minants of survival are urgently needed.
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